hat
ZFNs yo, yo soti pou travay en deyò kò sa a sou cellules extrait de san malad la. Les cellules modifié ki te retounen nan espwa pou kreye yon popilasyon de à VIH T-cellules ki ka goumen viris la. Jis renmen ak Crispr, kliyan ki fèt pou ZFNs, ki vini tankou yon pè kote yon estrikti protéines contenant Zenk molécules fè sa a ap mennen, koupe DNA a nan yon précis kote-a CCR5 jèn-devan natirèl sèlil a men f reparasyon pwosesis coup, frapper deyò a jèn. "Li vrèman illustre pouvwa ki posib pou move maladi ap trete yon malad,"te di Jennifer Doudna.
eng
The ZFNs are put to work outside the body on cells extracted from the patient’s blood. The edited cells are returned in the hope of creating a population of HIV-resistant T-cells that can fight the virus. Just like with Crispr, the custom-designed ZFNs, which come as a pair where a protein structure containing zinc molecules does the guiding, cut the DNA in a precise location – the CCR5 gene – before the cell’s natural but inaccurate repair process kicks in, knocking out the gene. “It really illustrates the power of the approach for treating disease,” says Jennifer Doudna.